Skip to main content
SpringerLink
Log in

Anti-diabetes Research in India: Contributions from Industrial Organizations

  • Chapter
  • First Online:
Drug Discovery and Drug Development

  • 642 Accesses

Abstract

The various aspects of past, present, and future of anti-diabetes research in India are covered here. A brief introduction on prevalence of diabetes in India followed by anti-diabetes drugs currently available is presented. Contributions made by various industrial R&Ds and organizations are mainly highlighted with the particular focus on organic molecules that were discovered and developed as potential anti-diabetes agents or drugs. Other agents or formulations or repositioned existing agents, etc., are generally not covered. A brief overview of leading molecules that either launched or reached to various stages of clinical trials is presented along with their chemical structure or class and mechanism of action wherever possible and the current status if known. These include balaglitazone (DRF-2593) and ragaglitazar (DRF-2725) of Dr Reddy’s Lab Ltd, saroglitazar (ZYH1) of Zydus Cadila, melogliptin (GRC-8200) of Glenmark Pharmaceuticals, BLX-1002 of Orchid Pharma, etc. Attempt was also made to provide the current status of anti-diabetes research worldwide along with that in India. The targets or agents currently being pursued include G-protein-coupled receptors, glucokinase activators, new incretin mimetics, SGLT2 inhibitors, etc. A list of molecules currently being pursued in India is also included. Finally, the future of anti-diabetes research in India along with the commentary on way forward is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adis Insight (n.d.-a) Drug profile BLX 1002. https://adisinsight.springer.com/drugs/800019061. Accessed 24 Jan 2019

  • Adis Insight (n.d.-b) Drug profile GKM 002. https://adisinsight.springer.com/drugs/800038106. Accessed 24 Jan 2019

  • Agrawal R, Jain P, Dikshit SN (2012) Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Mini-Rev Med Chem 12:87–97

    Article  CAS  PubMed  Google Scholar 

  • Anthony J, Kelkar A, Wilankar C, Ranjith V, Bhumra SK, Mutt S, Deka N, Sivaramakrishnan H, Sharma S, Marita AR (2013) Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One 8:e77946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Anupindi R, Sharma R, Husain R (2016) KBRPL2001, a novel GPR120 agonist, improves insulin sensitivity, glucose tolerance and decreases hepatic steatosis in rodent models of type 2 diabetes. In: ADA 2016—American Diabetes Association 76th Scientific Sessions, New Orleans, LA, USA, 10–14 June 2016

    Google Scholar 

  • Argenta Discovery (2007) Argenta Discovery and Dr. Reddy’s progress pre-clinical anti-inflammatory candidate to treat chronic respiratory disease. http://www.mvm.com/upload/news/downloads/26112007Argenta%20Press%20Release.pdf. Accessed 23 Jan 2019

  • Bahekar RH, Lohray BB, Lohray VB, Jain MR, Banerjee KM, Patel PR (2008) Antidiabetic compounds. Cadila Healthcare Ltd., Ahmedabad, Gujarat, India, PCT Pat. Appl. WO2008/062457 A2, 29 May 2008

    Google Scholar 

  • Bahekar R, Jain MR, Patel PR (2011) Short chain peptidomimetics based orally active GLP-1 agonist and glucagon receptor antagonist. Cadila Healthcare Ltd., Ahmedabad, India, PCT Pat. Appl. WO2011/048614A2, 28 Apr 2011

    Google Scholar 

  • Bailey CJ, Tahrani AA, Barnett AH (2016) Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes Endocrinol 4:350–359

    Article  CAS  PubMed  Google Scholar 

  • Bronson J, Black A, Dhar M, Ellsworth B, Merritt JR (2014) Chapter Twenty Seven-To market, to market – 2013. In: Desai MC (ed) Annual reports in medicinal chemistry, vol 49. Elsevier, Amsterdam, pp 437–508

    Google Scholar 

  • Businessworld (2014) Death of a dream. http://www.businessworld.in/article/Death-Of-A-Dream/08-11-2014-65256/. Accessed 24 Jan 2019

  • Cadila Healthcare (2000–2016) Annual reports, Corporate presentations. http://zyduscadila.com/

  • Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R (2003) Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol 140:527–537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chatterjee S, Majumder A, Roy S (2015) Observational study of effects of saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes. Sci Rep 5:7706. https://doi.org/10.1038/srep07706

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • ClinicalTrials.gov (2012a) A clinical trial to evaluate the safety and efficacy of ZYH7 compared to fenofibrate in patients with dyslipidemia. US National Library of Medicine, Bethesda, MD. NLM Identifier: NCT01539616. https://clinicaltrials.gov/ct2/show/record/NCT01539616. Accessed 23 Jan 2019

    Google Scholar 

  • ClinicalTrials.gov (2012b) Study of single ascending doses of PBL-1427 in healthy volunteers. US National Library of Medicine, Bethesda, MD. NLM Identifier: NCT01554293. https://clinicaltrials.gov/ct2/show/NCT01554293. Accessed 24 Jan 2019

    Google Scholar 

  • Cola JR (2015) Discontinued drug therapies to treat diabetes in 2014. Expert Opin Investig Drugs 24:1241–1245

    Article  CAS  Google Scholar 

  • Dandekar V (2016) Amidst crisis, Tata Group’s pharma unit advinus therapeutics lays off 50 people. The Economic Times. http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/amidst-crisis-tata-groupspharma-unit-advinus-therapeutics-lays-off-50-people/articleshow/55424515.cms. Accessed 11 Dec 2016

  • De Ceuninck F, Kargar C, Ilic C, Caliez A, Rolin JO, Umbdenstock T, Vinson C, Combettes M, de Fanti B, Harley E, Sadlo M, Lefèvre AL, Broux O, Wierzbicki M, Fourquez JM, Perron-Sierra F, Kotschy A, Ktorza A (2013) Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 168:339–353

    Article  PubMed  CAS  Google Scholar 

  • De Pablos-Velasco P, Parhofer KG, Bradley C, Eschwege E, Gönder-Frederick L, Maheux P, Wood I, Simon D (2014) Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol 80:47–56

    Article  CAS  Google Scholar 

  • DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL, INT131-007 Study Group (2014) Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? Diabetes Care 37:1918–1923

    Article  CAS  PubMed  Google Scholar 

  • Desai RC, Bahekar R, Jadav P, Goswami A, Patel P (2014) 2-Phenyl-5-heterocyclyl-tetrahydro-2H-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders. Cadila Healthcare Ltd., Ahmedabad, Gujarat, India, PCT Pat. Appl. WO2014/061031 A1

    Google Scholar 

  • Differding E (2017) The drug discovery and development industry in India-two decades of proprietary small-molecule R&D. Chem Med Chem 12:786–818. See this reference: For an in-depth analysis and comprehensive overview

    Article  CAS  PubMed  Google Scholar 

  • Dikshit M, Dikshit DK (2016) Drug discovery research in India. Curr Sci 111:252–255. See this reference: For a commentary

    Google Scholar 

  • Dr. Mohan’s Diabetes Specialities Centre (n.d.). https://drmohans.com/. Accessed 25 Jan 2019

  • Dr. Reddy’s Laboratories BusinessWire (2005) Dr. Reddy’s announces the formation of perlecan pharma. http://www.businesswire.com/news/home/20050927006290/en/Dr.-Reddys-Announces-Formation-Perlecan-Pharma-Perlecan#.VFofh00tC70. Accessed 23 Jan 2019

  • Erion DM, Lapworth A, Amor PA, Bai G, Vera NB, Clark RW, Yan Q, Zhu Y, Ross TT, Purkal J, Gorgoglione M, Zhang G, Bonato V, Baker L, Barucci N, D’Aquila T, Robertson A, Aiello RJ, Yan J, Trimmer J, Rolph TP, Pfefferkorn JA (2014) The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One 9(5):e97139. https://doi.org/10.1371/journal.pone.0097139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Filipski KJ, Pfefferkorn JA (2014) A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014. Expert Opin Ther Pat 24:875–891

    Article  CAS  PubMed  Google Scholar 

  • Filipski KJ, Stevens BD, Pfefferkorn JA (2012) Glucokinase activators in development. In: Jones RM (ed) New therapeutic strategies for type 2 diabetes: small-molecule approaches. RSC Publishing, Cambridge, pp 88–108

    Chapter  Google Scholar 

  • Frampton JE (2018) Empagliflozin: a review in type 2 diabetes. Drugs 78:1037–1048. https://doi.org/10.1007/s40265-018-0937-z

    Article  CAS  PubMed  Google Scholar 

  • Garber AJ, Abrahamson MJ, Barzilay J, Blonde L, Bloomgarden Z, Bush M, Dagogo-Jack S, Davidson M, Einhorn D, Garvey W, Grunberger G, Handelsman Y, Hirsch I, Jellinger P, McGill J, Mechanick J, Rosenblit P, Umpierrez G, Davidson M (2013) AACE comprehensive diabetes management algorithm 2013 consensus statement. Endocr Pract 19(Suppl 2):1–48. https://doi.org/10.4158/EP13176.CSUPPL

    Article  Google Scholar 

  • Giri P, Patel N, Patel B, Patel H, Bahekar R, Srinivas NR, Patel PR, Desai R (2017) Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: an application for toxicokinetic study in rats. Biomed Chromatogr 31:e3984. https://doi.org/10.1002/bmc.3984

    Article  CAS  Google Scholar 

  • Goldenberg R, Gantz I, Andryuk PJ, O’Neill EA, Kaufman KD, Lai E, Wang YN, Suryawanshi S, Engel SS (2017) Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 19:394–400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gopalan B, Ravi D, Rasheed M, Sreedhara SKH, Ishtiyaque A (2007) Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them. Matrix Laboratories Ltd., Secunderabad, India, PCT Pat. Appl. WO2007/113634 A1, 11 Oct 2007

    Google Scholar 

  • Gupta S, Walunj SS, Tokala RK, Parsa KVL, Singhand SK, Pal M (2009) Emerging drug candidates of dipeptidyl peptidase iv (DPP IV) Inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 10:71–87

    Article  CAS  PubMed  Google Scholar 

  • Gupta BP, Sharma I, Kohli N, Sharma S, Rathi A, Sharma AK (2017) Preliminary clinical assessment and non-toxicity evaluation of an Ayurvedic formulation BGR-34 in NIDDM. Euro J Pharm Med Res 4:302–311

    Google Scholar 

  • Gupta BP, Sharma I, Kohli N, Sharma S, Rathi A, Sharma AK (2018) Preliminary clinical assessment and non- toxicity evaluation of an ayurvedic formulation BGR-34 in NIDDM. J Tradit Complement Med 8:506–514. https://doi.org/10.1016/j.jtcme.2017.11.00

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gupta RC, Chhipa L, Mandhare AB, Nadkarni SS, Joshi D, Zambad S, Pathak P, Chauthaiwale V, Dutt C (n.d.) Design and synthesis of novel thiazolidine and pyrrolidine derivatives as DPP-IV inhibitors. https://www.technologynetworks.com/drug-discovery/posters/design-and-synthesis-of-novel-thiazolidine-and-pyrrolidine-derivatives-as-dppiv-inhibitors-230478. Accessed 24 Jan 2019

  • Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, Baron MA (2014) Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complicat 28:393–398

    Article  Google Scholar 

  • Huan Y, Jiang Q, Li G, Bai G, Zhou T, Liu S, Li C, Liu Q, Sun S, Yang M, Guo N, Wang X, Wang S, Liu Y, Wang G, Huang H, Shen Z (2017) The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Sci Rep 7:4351. https://doi.org/10.1038/s41598-017-04633-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Inagaki N, Onouchi H, Maezawa H, Kuroda S, Kaku K (2015) Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. Lancet Diabetes Endocrinol 3:191–197

    Article  CAS  PubMed  Google Scholar 

  • Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379. https://doi.org/10.2337/dc12-0413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jain R, Trehan S, Das J, Singh N, Nanda GK, Magadi SK, Sharma SK (2009) Novel heterocyclic compounds. Panacea Biotec Ltd., New Delhi, India, PCT Pat. Appl. WO2009/093269 A1, 30 Jul 2009

    Google Scholar 

  • Jain MR, Joharapurkar AA, Bahekar RH, Patel H, Jadav P, Kshirsagar SG, Patel VJ, Patel KN, Ramanathan VK, Patel PR, Desai RC (2015) Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor. J Diabetes 7:708–717. https://doi.org/10.1111/1753-0407.12233

    Article  CAS  PubMed  Google Scholar 

  • Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Joshi S (2014) A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther 16:63–71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068–1083

    Article  CAS  PubMed  Google Scholar 

  • Khan SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O’Neill MC, Zinman B, Viberti G, ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2443

    Article  Google Scholar 

  • Khanna I, Pillarisetti S (2014) Methods and compositions for treatment of diabetes and dyslipidemia. Kareus Therapeutics S.A., La Chaux-de-Fonds, Switzerland, US Pat. US8.623.897 B2, 7 Jan 2014

    Google Scholar 

  • Kharul R, Jain MR, Patel PR (2011) Substituted benzamide derivatives as glucokinase (GK) activators. Cadila Healthcare Ltd., Ahmedabad, India, PCT Pat. Appl. WO2011/013141 A2, 3 Feb 2011

    Google Scholar 

  • Kodimuthali A, Prasunamba PL, Pal M (2010) Synthesis of a novel analogue of DPP-4 inhibitor Alogliptin: introduction of a spirocyclic moiety on the piperidine ring. Beilstein J Org Chem 6:71. https://doi.org/10.3762/bjoc.6.71

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kushwaha RN, Haq W, Katti SB (2014) Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective. Curr Med Chem 21:4013–4045

    Article  CAS  PubMed  Google Scholar 

  • Lampueta P, Zambrowicz B, Strumph P, Sands A (2015) Development of sotagliflozin, a dual sodium-dependent glucose transporter ½ inhibitor. Diabetes Vas Dis Res 12:101–110

    Article  CAS  Google Scholar 

  • Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T (2015) Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58:7370–7380

    Article  CAS  PubMed  Google Scholar 

  • Linjawi S, Bode BW, Chaykin LB, Courrèges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW (2017) The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther 8:101–114

    Article  CAS  PubMed  Google Scholar 

  • Lohray VB, Lohray BB, Paraselli RB, Ramanujam R, Chakrabarti R (1999) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them. Dr. Reddy’s Research Foundation, Hyderabad, India, PCT Pat. Appl. WO1999/008501 A2

    Google Scholar 

  • Lupin Ltd (2001–2016) Annual reports. http://www.lupin.com/archives-annual-report.php

  • Maji D, Samanta S (2015) A review on the role of PPARÎ3 agonist and hybrids in type 2 diabetes and cardiomyopathy. Asian J Pharm Clin Res 8:26–31. https://innovareacademics.in/journals/index.php/ajpcr/article/view/3993

    CAS  Google Scholar 

  • Mancini AD, Poitout V (2015) GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit. Diabetes Obes Metab 17:622–629

    Article  CAS  PubMed  Google Scholar 

  • Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399–416

    Article  CAS  PubMed  Google Scholar 

  • Matschinsky FM (2013) GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 34:90–99

    Article  CAS  PubMed  Google Scholar 

  • Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, Taub R, Grimsby J (2006) The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 55:1–12

    Article  CAS  PubMed  Google Scholar 

  • Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, Davies MJ, Kaufman KD, Goldstein BJ (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34:2560–2566

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mookhtiar KA (2015) Liver-selective glucokinase activation for treating type 2 diabetes: translation from mouse to man. In: Ramanbhai Foundation 7th International Symposium on Current Trends in Pharmaceutical Sciences, Ahmedabad, India, 2015

    Google Scholar 

  • Nag B, Nag A, Dey D, Agarwal SK (2004) Amino acid phenoxy ethers. US Patent Application No: 6794401, 21 Sep 2004

    Google Scholar 

  • Nakamura A, Terauchi Y (2015) Present status of clinical deployment of glucokinase activators. J Diabetes Investig 6:124–132

    Article  CAS  PubMed  Google Scholar 

  • Novo Nordisk A/S (2015) Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes (PIONEER 3). https://clinicaltrials.gov/ct2/show/NCT02607865. Accessed 24 Jan 2019

  • Ohishi T, Yoshida S (2012) The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Investig Drugs 21:321–328

    Article  CAS  PubMed  Google Scholar 

  • Pal M (2009a) Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discov Today 14:784–792

    Article  CAS  PubMed  Google Scholar 

  • Pal M (2009b) Medicinal chemistry approaches for glucokinase activation to treat type 2 diabetes. Curr Med Chem 16:3858–3874

    Article  CAS  PubMed  Google Scholar 

  • Panacea Biotec (2003–2016) Annual reports. http://www.panacea-biotec.com/

  • Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC (2017) Is the inhibition of dipeptidyl peptidase-4 (DDP-4) enzyme route dependent and/or driven by high peak concentration? Seeking answers with ZYDPLA1, a novel long acting DPP-4 inhibitor, in a rodent model. Drug Res (Stuttg) 67:223–227. https://doi.org/10.1055/s-0042-122776

    Article  CAS  Google Scholar 

  • Pingali H, Zaware P, Jain M (2010) Novel GPR119 agonists. Cadila Healthcare Ltd., Ahmedabad, India, PCT Pat. Appl. WO2010/146605 A1, 23 Dec 2010

    Google Scholar 

  • Pirags V, Lebovitz H, Fouqueray P (2012) Imeglimin, a novel oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 14:852–858

    Article  CAS  PubMed  Google Scholar 

  • Piramal (1997–2016) Annual reports. http://www.piramal.com/investors/financial-reports#parentVertical-Tab2

  • Qaseem A, Humphrey L, Sweet D, Starkey M, Shekelle P, Clinical Guidelines Committee of the American College of Physicians (2012) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 156:218–231. https://doi.org/10.7326/0003-4819-156-3-201202070-00011

    Article  PubMed  Google Scholar 

  • Ranga MG, Rao JMR, Gudla CS (2015) Substituted bicyclic heteroaryl compounds as RXR agonists. Connexios Life Sciences Pvt. Ltd., Bangalore, India, PCT Pat. Appl. WO2015/107549 A1, 23 Jul 2015

    Google Scholar 

  • Rao JMR, Arumugam N, Ansari MM, Gudla C, Pachiyappan S, Ramalingam M, George J, Arul GF, Bommegowda YK, Angupillai SK, Kottamalai R, Jidugu P, Rao DS (2012) Agonists of GPR40. Connexios Life Sciences Pvt. Ltd., Bangalore, India, PCT Pat. Appl. WO2012/011125 A1, 26 Jan 2012

    Google Scholar 

  • Rao JMR, Venkatesham U, George J, Fernand G, Doppalapudi SR, Madhavan GR, Arumugam N, Ansari M, Murugavel K, Pradeep J, Allavuddeen S, Vijayaramalingam K, Prasad HS, Raj AM, Gnanavel S, Kottamalai R, Babu NMPS, Kenchegowda BY (2013) Cyclic amide derivatives as inhibitors of 11b-hydroxysteroid dehydrogenase and uses thereof. Connexios Life Sciences Pvt. Ltd., Bangalore, India, PCT Pat. Appl. WO2013/128465 A1, 6 Sep 2013

    Google Scholar 

  • Rao JMR, Ranga MG, Pachiyappan S (2014a) Olefin substituted oxindoles having AMPK activity. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, PCT Pat. Appl. WO2014/202528 A1, 24 Dec 2014

    Google Scholar 

  • Rao JMR, Ranga MG, Pachiyappan S (2014b) Spiro-substituted oxindole derivatives having AMPK activity. Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, PCT Pat. Appl. WO2014/202580 A1, 24 Dec 2014

    Google Scholar 

  • Reddy KA (2015) An unfinished agenda: my life in the pharmaceutical industry. Penguin Books India Pvt. Ltd., Gurgaon. http://www.drreddys.com/our-story/our-heritage/an-unfinished-agenda/

    Google Scholar 

  • Reddy DS, Saxena C, Komirishetty K (2015) Novel indazole compounds and a process for the preparation thereof. Council of Scientific & Industrial Research, New Delhi, India, Shantani Proteome Analytics Pvt. Ltd., Pune, India, PCT Pat. Appl. WO2015/015519 A1, 5 Feb 2015

    Google Scholar 

  • Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M, LixiLan-O Trial Investigators (2016) Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus Lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care 39:2026–2035

    Article  CAS  PubMed  Google Scholar 

  • Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR (2004) Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27:1324–1329. https://doi.org/10.2337/diacare.27.6.1324

    Article  CAS  PubMed  Google Scholar 

  • Sakhardande R, Kulkarni V, Sachan N, Nimbalkar M (2010) N-biphenylacyl thiazolidine-2,4-dione derivatives, their synthesis and uses. Elder Pharmaceuticals Ltd., Mumbai, India, PCT Pat. Appl. WO2010/082212 A2, 22 Jul 2010

    Google Scholar 

  • Sanofi (2018) FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes. http://www.news.sanofi.us/2018-05-22-FDA-to-review-Zynquista-TM-sotagliflozin-as-potential-treatment-for-type-1-diabetes. Accessed 24 Jan 2019

  • Saxena C (2015a) A “first-in-class” pre-IND compound for management of type-2-diabetes. In: 2015 BIO International Convention, Philadelphia, 15–18 June 2015

    Google Scholar 

  • Saxena C (2015b) Shantani corporate overview 2014–2015

    Google Scholar 

  • Singh SK, Manne N, Pal M (2008) Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: a key intermediate for dipeptidyl peptidase IV inhibitors. Beilstein J Org Chem 4:20. https://doi.org/10.3762/bjoc.4.20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sridharan R (1998) Can the chemistry change at Dr. Reddy’s? Business Today – corporate front: strategy. http://archives.digitaltoday.in/businesstoday/22051998/cf2.html. Accessed 24 Jan 2019

  • Swamy D (2012) Glenmark: will innovation pay?. http://forum.valuepickr.com/t/glenmark-will-innovation-pay/286. Accessed 23 Jan 2019

  • Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182–197

    Article  CAS  PubMed  Google Scholar 

  • The Pharmatimes (2012) Advinus’ GK-activator achieves early POC for diabetes. http://thepharmatimes.in/advinus-gk-activator-achieves-early-poc-for-diabetes/. Accessed 24 Jan 2019

  • The Times of India (2013) Zydus Group launches new diabetic drug. https://timesofindia.indiatimes.com/business/india-business/Zydus-Group-launches-new-diabetic-drug/articleshow/20459662.cms. Accessed 23 Jan 2019

  • Thomas A, Gopalan B, Lingam PRVS, Shah DM (2006) Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation. Glenmark Pharmaceuticals S.A., Neuchatel, Switzerland, PCT Pat. Appl. WO2006/040625 A1, 20 Apr 2006

    Google Scholar 

  • Times of India (2016) CSIR launches Ayurveda based anti diabetic drug for Rs 5 per tablet. http://timesofindia.indiatimes.com/articleshow/52503738.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

  • Valentine V, Goldman J, Shubrook JH (2017) Rationale for, initiation and titration of the basal insulin/GLP-1RA fixed-ratio combination products, IDegLira and IGlarLixi, for the management of type 2 diabetes. Diabetes Ther 8:739–752

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vuylsteke V, Chastain LM, Maggu GA, Brown C (2015) Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs R&D 15:227–232. https://doi.org/10.1007/s40268-015-0099-3

    Article  CAS  Google Scholar 

  • Wysham CH, MacConell L, Hardy E (2016) Efficacy and safety of multiple doses of exenatide once-monthly suspension in patients with type 2 diabetes: a phase II randomized clinical trial. Diabetes Care 39:1768–1776

    Article  CAS  PubMed  Google Scholar 

  • Zhang F, Dey D, Bränström R, Forsberg L, Lu M, Zhang Q, Sjöholm Å (2009) BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner. Am J Phys Cell Phys 296:C346–C354

    CAS  Google Scholar 

  • Zhu D, Gan S, Liu Y, Ma J, Dong X, Song W, Zeng J, Wang G, Zhao W, Zhang Q, Li Y, Fang H, Lv X, Shi Y, Tian H, Ji L, Gao X, Zhang L, Bao Y, Lei M, Li L, Zeng L, Li X, Hou X, Zhao Y, Hu T, Ge X, Zhao G, Li Y, Zhang Y, Chen L (2018a) Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Diabetes Endocrinol 6:627–636

    Article  CAS  PubMed  Google Scholar 

  • Zhu XX, Zhu DL, Li XY, Li YL, Jin XW, Hu TX, Zhao Y, Li YG, Zhao GY, Ren S, Zhang Y, Ding YH, Chen L (2018b) Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab 20:2113–2120. https://doi.org/10.1111/dom.13338

    Article  CAS  PubMed  Google Scholar 

  • Zydus Cadila (2011) Zydus’ IND application of ZYGK1 for treating diabetes receives USFDA approval (Press Note). http://www.zydususa.com/Press%20Releases/2011/April%207%20-%20IND%20Application%20of%20ZYGK1%20Receives%20USFDA%20Approval.pdf

Download references

Acknowledgement

MP thanks management of Dr. Reddy’s Institute of Life Sciences, Hyderabad for encouragement and support.

Author information

Authors and Affiliations

  1. Department of Chemistry, MNR Degree and PG College, Hyderabad, India

    Sarbani Pal

  2. Dr. Reddy’s Institute of Life Sciences, Hyderabad, India

    Manojit Pal

  3. Manipal Academy of Higher Education, Manipal, Karnataka, India

    Manojit Pal

Authors
  1. Sarbani Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manojit Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. NCR Biotech Science Cluster, Translational Health Science and Technology Institute, Faridabad, India

    Madhu Dikshit

Additional information

Dedicated to late Dr. K. Anji Reddy (the founder-chairman of Dr. Reddy’s Laboratories Limited, Hyderabad) on the occasion of his 80th birthday (Feb 1, 1939).

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pal, S., Pal, M. (2021). Anti-diabetes Research in India: Contributions from Industrial Organizations. In: Dikshit, M. (eds) Drug Discovery and Drug Development. Springer, Singapore. https://doi.org/10.1007/978-981-15-8002-4_8

Download citation

Publish with us

Policies and ethics

Search

Navigation